Analysts Offer Predictions for LXEO Q1 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Lexeo Therapeutics in a research note issued on Monday, March 24th. Leerink Partnrs analyst M. Foroohar expects that the company will earn ($0.80) per share for the quarter. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.79) EPS and Q4 2025 earnings at ($0.79) EPS.

Several other equities research analysts have also recently issued reports on the stock. Leerink Partners decreased their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday. Royal Bank of Canada decreased their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Chardan Capital reissued a “buy” rating and issued a $25.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Stock Down 10.1 %

LXEO opened at $3.99 on Wednesday. Lexeo Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.50. The business has a 50-day moving average of $4.09 and a two-hundred day moving average of $6.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The stock has a market capitalization of $131.93 million, a price-to-earnings ratio of -1.26 and a beta of 3.85.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of large investors have recently added to or reduced their stakes in LXEO. Geode Capital Management LLC boosted its position in Lexeo Therapeutics by 86.5% in the 3rd quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after buying an additional 256,635 shares during the last quarter. State Street Corp lifted its stake in Lexeo Therapeutics by 29.4% during the third quarter. State Street Corp now owns 253,946 shares of the company’s stock worth $2,296,000 after purchasing an additional 57,674 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in Lexeo Therapeutics in the third quarter worth $11,307,000. Barclays PLC boosted its holdings in Lexeo Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock worth $454,000 after purchasing an additional 31,057 shares during the period. Finally, Janus Henderson Group PLC increased its stake in Lexeo Therapeutics by 18.9% during the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after purchasing an additional 599,203 shares during the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.